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Abstract
Purpose Breast cancer patients undergoing axillary lymph
node dissection (ALND) are at risk of lymphedema (LE).
Successful management of LE relies on early diagnosis
using sensitive modalities. In the current study, we
explored the effectiveness of a surveillance program for
lymphedema management (SLYM) compared to standard
care.
Methods Breast cancer patients who underwent ALND in
Seoul National University Bundang Hospital from January
2008 to December 2015 were included in this prospective
study. The SLYM commenced in May 2011. The LE
outcomes of patients treated prior to initiation of the SLYM
were compared with those of patients after SLYM
implementation.
Results A total of 707 patients were included, 390 in the
SLYM group and 317 in the historical control (HC) group.
A total of 203 patients (28.7 %) had episodes of all-stage
LE during follow-up. Of these, 126 (19.7 %) were in the
surveillance group and 77 (24.3 %) in the HC group. The
overall 5-year cumulative incidence of LE (greater than
stage 3) was 25 (95 % CI 15.4–34.6) (6.4 %) in the SLYM
group and 48 (95 % CI, 15.4–34.6) (15.1 %) in the HC
group. In the SLYM group, poor compliance had a sig-
nificant impact on LE incidence (OR = 2.98, P = 0.002).
Low level of self-monitoring and insight scores were sig-
nificantly related to LE incidence (OR = 1.31, P = 0.025)
after adjusting for age, body mass index, the type of sur-
gery chosen, radiation therapy, and chemotherapy. With a
cut-off of 29.5 days from operation to the first visit to the
LE clinic, the sensitivity was 60 % and the specificity 61 %
in terms of predicting a LE event.
Conclusions Surveillance improves LE prevention com-
pared to clinical evaluation. The first visit to the LE clinic
should be made within 1 month after surgery. In the first
year, visits should be made at intervals of less than
3 months.
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Introduction
Breast cancer survivors are at increased risk for the
development of breast cancer-related lymphedema
(BCRL), a chronic, debilitating, and disfiguring condition
that is progressive and requires lifelong self-management
of symptoms. Lymphedema (LE) is caused by a disruption
of the lymphatic system that, in the initial stages, leads to
fluid accumulation in the interstitial tissue spaces, and
eventually manifests clinically as swelling of the arm,
breast, shoulder, neck, or torso [1]. Early assessment and
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intervention may be important to correct subtle subclinical
LE that, if left untreated, may progress to chronic and
severe LE. Previous studies suggested that regular
surveillance of upper-body morbidities such as LE should
be integrated into the routine postoperative care of women
with breast cancer, as early diagnosis potentially con-
tributes to more effective management, and prevention of
progression of troublesome conditions [2].
Detection and management of early-stage LE may pre-
vent progression to chronic disabling disease [3] and may
enable cost-effective conservative intervention. Fu et al. [4]
found that patient education on the early signs and symp-
toms of upper-body morbidity, in particular disease pro-
gression, was important. Bioimpedance spectroscopy (BIS)
assesses changes in extracellular fluid levels and can
identify such changes in limbs prior to clinical presentation
(thus before the condition becomes non-pitting [fibrotic]
[5]). A short trial showed that compression garments
effectively treated subclinical LE [6]. A systematic review
revealed that compression garments and bandages reduced
the volume of cancer-related LE.
A prospective surveillance model may be useful to
detect BCRL at an early stage, when the opportunities to
reduce risk or slow progression are optimal. A surveillance
program would allow healthcare providers to detect BCRL
symptoms early, affording better opportunities to prevent
progression to the subclinical stage and to institute con-
tinuous care plans from the inpatient to the outpatient
settings [6]. Few rigorous comparative research studies
have been performed on patients with BCRL, compro-
mising the development of evidence-based assessment of,
and treatments for, hundreds of thousands of women who
have, or are at risk for the development of, BCRL.
Therefore, we hypothesized that a surveillance program
featuring the use of extracellular water (ECW) ratio to
detect subclinical LE might be effective to prevent the
development of LE of stages 2 and 3 after surgery.
The purpose of our study was thus to evaluate the effi-
cacy of a surveillance program including ECW ratio
measurement in terms of detection of subclinical LE; we
explored whether such detection might prevent the devel-
opment of advanced LE (stages 2 and 3) after surgery.
Patients and methods
Study design
We accessed the database of the Seoul National University
Bundang Hospital and extracted records made from Jan-
uary 1, 2008, through to December 31, 2015. We collected
data on women aged 19–99 years who were newly diag-
nosed with stage 1–3 unilateral breast cancer and who had
undergone breast cancer surgery with axillary lymph node
dissection (ALND). This was thus a single-center obser-
vational study. Clinical characteristics, demographic
information, treatment details, and LE status upon follow-
up were all recorded in our clinical database warehouse
system. A surveillance program for LE management
(SLYM) commenced in May 2011. We sought to identify
patients with early-stage LE and institute management at
that time.
The 767 patients were divided into three groups: one
historical comparison (HC) group treated prior to imple-
mentation of the surveillance program (thus, from 2008
through 2010; HC group, n = 317); those who were
screened from 2010 to 2011 (group B, n = 60); and a
current group (treated from 2011 through 2015) who were
participating in the surveillance program (SLYM group,
n = 390).
The primary aim of our study was to compare the event-
free survival rate between the HC and SLYM groups. This
was defined as survival without advanced LE. LE was
defined by reference to the guidelines of the International
Society of Lymphology (ISL) consensus document. These
guidelines feature a staging system based on the amount of
swelling and the condition of the skin and tissues, and can
be used to identify disease progression and severity and the
potential for successful treatment. We defined the event of
interest as advanced LE (greater than stage 3). The sec-
ondary aim was to measure the incidence of LE of any
stage during follow-up.
Three physicians defined LE stages by reference to the
ISL criteria. Inter-rater agreement between physicians A (a
psychiatrist, EJY), B (a surgeon, SWK), and C (a surgeon,
EYK) was analyzed by calculation of kappa coefficients.
We used simple randomization to select representative
samples from the pre-surveillance (May 2010 to April
2011) (n = 45) and post-surveillance (May 2012 to April
2013) (n = 50) periods. Kappa coefficients were 0.87 and
0.93 in the pre- and post-surveillance period, respectively.
ICCs were 0.84 and 0.92 in the pre- and post-surveillance
period, respectively. Overall agreements (%) were 81.2 and
83.7 % in the pre- and post-surveillance period,
respectively.
Surveillance protocol
The SLYM program was implemented in May 2011 to
identify high-risk LE patients who would benefit from
comprehensive surveillance by a transdisciplinary team,
with an emphasis on early detection and prevention of LE.
A care plan was initiated immediately after surgery for all
patients who underwent ALND to identify patients at high
risk of LE.
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To detect subclinical LE, we used a reliable and valid
instrument, the breast cancer and lymphedema symptom
experience index [7, 8] and a multi-frequency bioelectrical
impedance analyzer (BIA) (Inbody S10 Biospace, Bio-
space Co. Ltd., Korea; Model JMW140), according to the
manufacturer’s instructions. The BIA estimates bodily
composition by comparing conductivity differences
between various tissues; these reflect the biological char-
acteristics of the tissues. Electrodes are placed at eight
precisely defined tactile points prior to multi-segmental
frequency analysis. A total of 30 impedance measurements
are obtained at six different frequencies (1, 5, 50, 250, 500,
and 1000 kHz) from the following five locations: the right
and left arms, the trunk, and the right and left legs. Each
single-frequency bioimpedance ratio is expressed as a
Zunaffected limb/Zaffected limb ratio, yielding LE index values
[1 [9].
The inclusion criterion for compressive intervention was
a diagnosis of subclinical LE. The diagnostic criteria
included subjective LE symptoms and an ECF ratio[1.066
at the dominant arm, or a ratio[1.106 at the non-dominant
arm. The garment provided was a 20–30 mm-Hg com-
pression sleeve (with a gauntlet) fitted by a trained nurse. If
the volume increased by [3 %, both a compression gar-
ment and education on manual lymphatic massage were
prescribed for 4 weeks.
If the clinical LE stage is greater than two, complete
decongestive therapy (CDT) performed by specially
trained LE therapists, is considered to be the international
standard of care [10, 11]. Such therapy seeks to move
lymphatic fluid to an area from which it may drain, thus
reducing swelling. The therapy features manual lymph
drainage, progressive active and action-assisted exercises,
and compression therapy [12].
If LE recurred, we checked the status thereof using the
same tools. Patients with stage 0 or 1 subclinical LE
commenced progressive strengthening exercises; they were
instructed in modified progressive weight-lifting exercises
[13]. Patients participated in a supervised program run in
the hospital and continued the program at home.
Strengthening exercises commenced with the aid of a
thera-band. After checking shoulder strength using a
manual muscle strength test, an appropriate thera-band was
prescribed, as was the number of exercise repetitions. This
number was progressively increased if no symptoms were
evident after three sessions. If the fluid volume decreased
after intensive treatment, the patients returned to 3-month
surveillance until 1 year after surgery, and were then
screened at 6-month intervals.
Compliance with the surveillance program was catego-
rized as good or poor by reference to the intervals between
visits to the LE clinic. The times from the day of operation
to the first visit to the LE clinic, and those between follow-
up days, were calculated. The cut-off intervals were
3 months (good compliance B 3 months; poor compliance
[3 months).
To assess health-related empowerment, patients were
asked to complete the Health Education Impact Question-
naire (HeiQ) at their first visit. The HeiQ is a well-vali-
dated, widely used instrument developed in Australia,
containing 40 questions exploring eight different domains
(health-directed behavior, positive and active life engage-
ment, emotional well-being, self-monitoring and insight,
constructive attitudes and approaches, skill and technique
acquisition, social integration and support, and health ser-
vice navigation) [14]. We analyzed the self-monitoring and
insight dimension scores (ranges 1.0–4.0) and categorized
them into low (1.0–2.0) and high level (3.0–4.0).
Historical control group (HC group)
In the HC group, LE was diagnosed when patients com-
plained of subjective symptoms, or by clinicians of our
multidisciplinary team. Patients who complained and those
with swelling on the operative site (noted by clinicians)
were referred to the LE clinic for further evaluation and
management. If LE was confirmed, CDT was applied.
Statistical considerations
The actuarial rates of irreversible LE were calculated using
the Kaplan–Meier method. All statistics were calculated
from the date of surgery. To isolate the effect of the SLYM
program, our calculation of the high risk-free survival rate
in the SLYM group included only survival without
advanced (over stage 3) LE. Cox’s proportional hazard
model was used to compare the high risk-free survival rates
between groups after adjusting for age, body mass index,
the number of cycles of chemotherapy given, and the
radiotherapy field. Only variables that were significant
upon univariate analysis were included in multivariate
analysis. Comparisons between groups were performed
with the aid of the log-rank test. P values \0.05 were
deemed to be statistically significant. All statistical tests
were two-sided and were performed with the aid of SPSS
(version 17.0) software (SPSS Inc., Chicago, IL).
Results
Patient characteristics
Patient and treatment characteristics are summarized in
Table 1. The median age at the time of surgery was
47.9 years (range, 23–89 years). Breast-conserving surgery
(BCS) was performed on 138 (35.4 %) and mastectomy on
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252 (64.6 %) patients in the SLYM group, and 28 (8.8 %)
and 289 (91.9 %) patients in the HC group. Chemotherapy
(doxetaxel) was administered to 280 patients (71.9 %) in
the SLYM group and 223 (70.3 %) in the HC group.
Radiotherapy was prescribed for 351 patients (90.0 %) in
the SLYM group, of whom 211 (54.0 %) received breast or
chest-wall irradiation alone, and for 276 in the HC group
(87.1 %), of whom 174 (54.9 %) received breast or chest-
wall irradiation alone.
Incidence and time course of LE
Initially, 203 patients (28.7 %) were found to have devel-
oped LE of any stage during follow-up. Of these, 126
(19.7 %) were in the SLYM group and 77 (24.3 %) in the
HC group. Of these patients, 131 (18.5 %) in whom LE had
resolved or improved at the next follow-up (thus after
6 months) were defined as having reversible LE. Of these
patients, 101 (33.6 %) were in the SLYM group and 30
(9.5 %) in the HC group. The initial stage of the first
swelling episode was two in 179 patients (25.3 % of all
patients; 116 in the SLYM group and 63 in the HC group)
and three in 24 patients (3.4 %) (Ten in the SLYM group
and 14 in the HC group). A total of 48 (6.8 %) patients who
were initially of stage 2 progressed to stage 3 (15 in the
SLYM group and 33 in the HC group).
The overall 5-year cumulative incidence of advanced
LE (greater than stage 3) was 25 (95 % CI 15.4–34.6
(6.4 %) in the SLYM group and 48 (95 % CI 15.4–34.6)
(15.1 %) in the HC group (Fig. 1). The median interval
from surgery to initial swelling in patients with advanced
LE was 25.4 months (95 % CI 18.6–32.1) in the SLYM
group and 20.7 months (17.0–24.5 months) in the HC
group.
The overall 5-year cumulative incidence of LE (any
stages) was 126 (95 % CI 106.8–145.2 (32.3 %) in the
SLYM group and 145 (95 % CI 127.6–162.4) (45.7 %) in
the HC group. The median interval from surgery to initial
swelling in patients with any stage of LE was 16.9 months
in the SLYM group and 18.4 months in the HC group. Of
the 77 affected patients, LE first occurred within 1 year of
diagnosis in 97 and 80 % of patients, and within 3 years in
89 and 62 %, in the SLYM and HC group, respectively.
Risk factors for LE
Upon multivariate analysis, the following treatment-related
factors were significantly correlated with an increased risk
of LE: chemotherapy with docetaxel (hazard ratio (HR)
4.98; P = 0.001) and radiotherapy on breast with SCRT
(HR 1.20; P = 0.045) (Table 2). The HR of the patho-
logical stage was 1.52, and lacked significance.
Risk factors for LE in the SLYM group
Table 3 shows the results of multivariate logistic regres-
sion modeling. Model 1 computed coefficients for a LE
event using demographic characteristics such as age, body
Table 1 Patient and treatment
characteristics
HC group
(N = 317), n (%)
SLYM group,
(N = 390), n (%)
Age at diagnosis (years) 48.6 ± 11.7 (25–82) 47.6 ± 10.7 (23–89)
BMI 23.3 ± 9.8 24.3 ± 9.5
Dominant side 132 (41.6 %) 207 (53.0 %)
Histopathologic stage
I(%) 92 (29.0 %) 109 (28.0 %)
II (%) 168 (53.0 %) 215 (55.0 %)
III (%) 57 (18.0 %) 66 (17.0 %)
Breast surgery
BCS 28 (8.8 %) 138 (35.4 %)
Mastectomy 289 (91.1 %) 252 (64.6 %)
Radiotherapy
Not done 41 (12.9 %) 47 (12.0 %)
Breast only 174 (54.9 %) 211 (54.0 %)
Breast and SCRT (%) 102 (32.2 %) 140 (36.0 %)
Chemotherapy
Doxetaxel 223 (70.3 %) 280 (71.9 %)
Cycle of doxetaxel 5.1 ± 0.3 6.1 ± 0.2
HC historical control, SLYM surveillance program for lymphedema management, BCS breast-conserving
surgery, SCRT supraclavicular radiation therapy
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mass index (BMI), and the dominant side. None of age,
BMI, or the operative site was significantly associated with
a LE event.
Model 2 incorporated cancer and treatment character-
istics, such as histopathological stage, type of breast sur-
gery, radiotherapy, and chemotherapy (docetaxel), in
addition to demographic characteristics. Chemotherapy and
radiotherapy on breast with SCRT were significantly rela-
ted to the development of LE events (OR = 5.56,
P = 0.032; OR = 2.02, P = 0.243, respectively).
Model 3 incorporated compliance with the surveillance
program in addition to demographic and treatment char-
acteristics. Chemotherapy and radiation therapy remained
significantly associated with LE events (OR = 5.55,
P = 0.041; OR = 2.01, P = 0.042, respectively). Poor
compliance had a significant impact on LE events
(OR = 2.98, P = 0.002). The low level of self-monitoring
and insight were significantly related to LE events
(OR = 1.31, P = 0.025) (Fig. 2).
We explored the sensitivity and specificity of a cut-off
value (days) from operation to the first visit to the LE
clinic in terms of predicting a LE event. With a cut-off of
29.5 days, the sensitivity was 60 % and the specificity
61 %. However, the area under the ROC curve was
0.6417, thus affording poor diagnostic utility. However,
29.5 days can be used as a reference value (Supplemen-
tary Table).
Discussion
The frequency of advanced LE after breast cancer surgery
was reduced on the introduction of a LE surveillance
program. The program afforded ten percentage points of
the total reduction in advanced LE among women invited















N at risk 12 mo 24 mo 36 mo 48 mo 60 mo 
Surveillance 144 94 57 49 1 
Probability 
(%) 
97 93 89 80 80 
Historical  119 85 47 18 2 
Probability 
(%) 
80 66 62 58 58 
Fig. 1 Kaplan–Meier with log-
rank analysis for the irreversible
lymphedema in the surveillance
group compared the historical
control group
Table 2 Multivariate analysis of risk factors associated with lym-
phedema (N = 707)
Clinical characteristics HR 95 % CI P valuea
Age (C60 years) 0.03 0.01–0.05 0.014
BMI (C25 kg/m2) 1.60 0.69–2.75 0.255
Dominant side 1.75 0.45–8.63 0.432
Histopathologic stage (CII) 1.52 0.73–3.11 0.321
Type of surgery (mastectomy) 1.17 0.42–3.29 0.766
Radiation therapy (breast with SCRT) 2.01 1.05–3.03 0.045
Chemotherapy (taxel) 4.98 1.93–12.87 0.001
Surveillance protocol 0.31 0.17–0.56 \0.001
HR hazard ratio, CI confidence interval, SCRT supraclavicular radi-
ation therapy
a Cox proportional hazards model
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made within 1 month after surgery. In the first year, visits
should be made at intervals of less than 3 months.
Early LE detection is important, and can prevent
development of irreversible disease. Surveillance can pre-
vent progression of subclinical LE [6]. No evidence-based
method for early detection of subclinical LE is yet avail-
able. Relevant clinical trials, using various surveillance
protocols, are in progress [15]. However, few rigorous
comparative studies on patients with BCRL have appeared,
compromising the development of evidence-based assess-
ment and treatment for women who have LE or are at risk
of LE development [15]. We found that the hazard ratio for
LE development was three times higher in the control than
the surveillance group.
We used BIS to measure extracellular fluid volumes;
BIS records the responses to an applied electrical current,
and is more sensitive and specific than conventional
methods [16]. BIS allows earlier recognition of subclinical
LE, before the disease is clinically evident upon tape
measurement of water displacement. Soran et al. [17]
reported that periodic monitoring of women at high risk of
LE, using BIS, facilitated early detection and timely
intervention.
Currently, the lack of data on appropriate assessment
frequency and the assessor skills required compro-
mise analyses of the cost-effectiveness of prospective
surveillance models for breast cancer survivors [18]. One
previous study [17] recorded measurements preoperatively,
at 3–6 months after surgery, and then annually for 5 years.
Other studies assessed patients five times: preoperatively
and every 3 months for the following year [6, 19]. Clearly,
such variations affect costs. The incremental benefits
afforded by surveillance at 3- versus 4- or 6-month inter-
vals warrants study [18]. We explored the sensitivity and
specificity of time from surgery to the onset of surveillance
in terms of predicting a LE event. Surveillance should
commence within 1 month of surgery; this should be
considered when planning clinical interventions and the
follow-up schedule. A previous study also suggested that
the first postoperative assessment visit should take place
within 1 month after surgery [20].
Of the patient-, treatment-, and disease-related factors,
chemotherapy with doxetaxel was associated with an
increased risk of LE. Neither age nor BMI correlated with
development of a LE event. An earlier study found that
these factors were, in fact, important [21], but another
study found no such correlations [22]. Radiation therapy of
the breast, and SCRT, were significantly associated with
Table 3 Multiple logistic regression analysis of patients with breast cancer in surveillance group (N = 390)
Variables Model 1 Model 2 Model 3
Age 1.01 (0.98–1.05) 1.01 (0.98–1.05) 1.02 (0.98–1.05)
BMI 1.02 (0.97–1.06) 1.02 (0.97–1.05) 1.03 (0.98–1.05)
Dominant side 1.05 (0.96–1.16) 1.06 (0.96–1.16) 1.06 (0.97–1.15)
Type of surgery (mastectomy) 1.70 (0.86–6.55) 1.67 (0.88–6.11)
Radiation therapy (breast with SCRT) 2.02 (1.06–3.11)* 2.01 (1.05–3.10)*
Chemotherapy (taxel) 5.56 (2.00–9.11)* 5.55 (1.99–9.01)*
Poor compliance (interval of follow-up[3 months) 3.16 (1.36–6.89)*
Low grade of self-monitoring and insight (score B2) 1.31 (1.03–3.24)*
Values are odds ratio (95 % CI)
Model 1: Age, BMI, and dominant side
Model 2: Model 1 ? histopathologic stage, type of surgery, radiation therapy, chemotherapy
Model 3: Model 2 ? compliance, self-monitoring, and insight
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Model 1 ROC area=0.5538 Model 2 ROC area=0.5906
Model 3 ROC area=0.6807 Reference
Fig. 2 ROC curve of lymphedema prediction in surveillance group
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LE development. Regional irradiation is considered to be a
significant risk factor for LE [23]. Irradiation of the breast
and SCRT increased the risk of LE compared to that
associated with breast irradiation alone [24]. The question
of whether chemotherapy is a risk factor for the develop-
ment of lymphedema remains controversial. Patients
receiving docetaxel-based chemotherapy were at an
increased risk of developing LE [21].
Adherence to self-management regimens must be
improved. Adherence to the surveillance program was
checked by recording the intervals between visits to the in-
hospital program. The self-monitoring and insight scales
capture the ability of an individual to monitor a medical
condition, triggering physical responses that create insight
and appropriate self-management [25]. We found that
adherence and self-monitoring were significantly associ-
ated with LE development. Visits should be at less than
5-month intervals. After adjusting for cancer and treatment
factors, compliance with the surveillance program
remained significant. Cancer patients require health-related
empowerment to manage the challenges of cancer and to
control their lives [26, 27]. Especially in patients at high
risk of LE, fear or denial operates against disease preven-
tion and management. All surveillance programs must seek
to empower patients; this is becoming increasingly
important [28].
Caution must be exercised before seeking to generalize
our results. Although our choice of a matched cohort may
minimize the risk of systematically overestimating the
effects of the surveillance program, the nonrandomized
design of our work is a major limitation. Is it possible that
the lead time created bias when the frequencies of incident-
based LE were calculated? We counted LE events devel-
oping after breast cancer surgery only if the LE was
diagnosed within a group. For example, in the surveillance
group, advanced LE was attributed to breast cancer only if
the disease was diagnosed early by means of surveillance
or was clinically diagnosed while the woman in question
was in fact in the group. However, for women diagnosed
early during surveillance, the initial clinical diagnosis
would have been made at an unknown time within the
study period. Thus, the lead time played no role when we
calculated LE rates. We believe, therefore, that the calcu-
lations for the two groups are free of such bias.
We evaluated the effects of a surveillance program
compared to self-reporting/clinical evaluation. Our results
provide a rationale for the future randomized clinical trials
required to validate our program in patients at high risk of
LE. We conclude that surveillance reduces the rate of LE
developing after surgery. The magnitude of the benefit was
modest. Most importantly, the apparent benefit afforded
by optimized patient care may be lost unless patients
are empowered in terms of self-assessment and
self-monitoring. The take-home message is that the LE
surveillance program achieved an absolute reduction of ten
percentage points in the frequency of advanced LE devel-
oping after breast cancer surgery.
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